Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Gains from Sales and Divestitures (2016 - 2025)

Historic Gains from Sales and Divestitures for Ptc Therapeutics (PTCT) over the last 9 years, with Q3 2025 value amounting to $1.2 million.

  • Ptc Therapeutics' Gains from Sales and Divestitures rose 2999.34% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 2999.34%. This contributed to the annual value of $963543.0 for FY2024, which is 467.74% up from last year.
  • Latest data reveals that Ptc Therapeutics reported Gains from Sales and Divestitures of $1.2 million as of Q3 2025, which was up 2999.34% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Gains from Sales and Divestitures ranged from a high of $1.2 million in Q3 2025 and a low of $298982.0 during Q1 2021
  • Moreover, its 5-year median value for Gains from Sales and Divestitures was $751448.0 (2023), whereas its average is $703866.5.
  • Per our database at Business Quant, Ptc Therapeutics' Gains from Sales and Divestitures soared by 8232.86% in 2023 and then skyrocketed by 467.74% in 2024.
  • Ptc Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $335114.0 in 2021, then soared by 50.65% to $504851.0 in 2022, then soared by 82.33% to $920488.0 in 2023, then grew by 4.68% to $963543.0 in 2024, then rose by 24.71% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q3 2025, $1.1 million for Q2 2025, and $1.1 million during Q1 2025.